2021
DOI: 10.3389/fonc.2021.768128
|View full text |Cite
|
Sign up to set email alerts
|

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Abstract: In the original article, there were mistakes in Table 2 as published. We collected data with reference to both the conference abstract version and the full-text published version of the TRANSCEND NHL 001 trial conducted by Abramson et al. (1, 2); in Table 2, we showed the data from the conference abstract version, which should be changed to the full-text version. The rest of the paper,

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 2 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?